Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Chief Medical Officer | February 02, 2021 | February 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date February 02, 2021 · Filed February 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.58 · Expires 2031-02-02 | Direct | 307,300 |
Reported balance
After 2021-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-02 · Grant · Acquired 307,300 · Balance 307,300 F1: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.58 · Expires 2031-02-02 | Direct | 307,300 |
Reported balance
After 2021-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-02 · Grant · Acquired 307,300 · Balance 307,300 F2: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022.
F2: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2021 Filed Feb 4, 2021 16:26 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007727 · doc4.xml · derivative · entry 2 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F2 · derivative.exercise_date: Represents a special retention award comprised of options to purchase common stock. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 16:26 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option (right to buy) · Derivative | 307,300 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0001209191-21-007727 · doc4.xml · derivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 307,300 Underlying: Common Stock · 307,300 shares Expires 2031-02-02 F1 · derivative.exercise_date: The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on February 2, 2022, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 2, 2022. Read SEC document |
| March 17, 2020 Filed Mar 18, 2020 10:37 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 15,606 | $3.63 | $56,649.78 |
DisclosureSEC source: 0001209191-20-019914 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,217 Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 17:22 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 226,000 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0001209191-20-017393 · doc4.xml · derivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2030-03-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 6, 2021, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 6, 2021. Read SEC document |
| November 12, 2019 Filed Nov 13, 2019 10:00 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 3,424 | $4.38 | $14,991.64 |
DisclosureSEC source: 0001209191-19-056260 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,611 Read SEC document |
| August 12, 2019 Filed Aug 13, 2019 11:46 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,639 | $6.10 | $9,997.90 |
DisclosureSEC source: 0001209191-19-045697 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,187 Read SEC document |
| May 17, 2019 Filed May 20, 2019 09:48 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,389 | $7.20 | $10,000.80 |
DisclosureSEC source: 0001209191-19-031229 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,548 Read SEC document |
| March 14, 2019 Filed Mar 14, 2019 14:35 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 4,638 | $6.47 | $29,993.95 |
DisclosureSEC source: 0001209191-19-019374 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,159 Read SEC document |
| January 18, 2019 Filed Jan 18, 2019 16:58 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 195,000 | $0.00 Strike: $7.53 | $0.00 |
DisclosureSEC source: 0001209191-19-004577 · doc4.xml · derivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,000 Underlying: Common Stock · 195,000 shares Expires 2029-01-18 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 18, 2020, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 18, 2020. Read SEC document |
| May 15, 2018 Filed May 16, 2018 13:16 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,586 | $5.87 | $15,174.39 |
DisclosureSEC source: 0001209191-18-030426 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,521 Read SEC document |
| March 14, 2018 Filed Mar 15, 2018 10:18 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,885 | $6.89 | $19,877.65 |
DisclosureSEC source: 0001209191-18-019762 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,935 Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 17:29 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 175,000 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001209191-18-002515 · doc4.xml · derivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2028-01-04 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on January 4, 2019, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 4, 2019. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 11:16 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,836 | $7.00 | $19,852.00 |
DisclosureSEC source: 0001209191-17-060196 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,050 Read SEC document |
| August 11, 2017 Filed Aug 11, 2017 13:34 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,479 | $6.05 | $14,997.95 |
DisclosureSEC source: 0001209191-17-048536 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,214 Read SEC document |
| May 11, 2017 Filed May 12, 2017 10:00 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 2,435 | $6.12 | $14,904.64 |
DisclosureSEC source: 0001209191-17-031715 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,735 Read SEC document |
| March 17, 2017 Filed Mar 20, 2017 08:19 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 4,233 | $9.49 | $40,171.17 |
DisclosureSEC source: 0001209191-17-021587 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,300 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 16:20 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 115,000 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001209191-17-017506 · doc4.xml · derivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2027-03-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 1, 2018, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 1, 2018. Read SEC document |
| November 22, 2016 Filed Dec 1, 2016 11:29 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 1,000 | $7.75 | $7,750.00 |
DisclosureSEC source: 0001209191-16-152591 · doc4.xml · nonDerivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,067 Read SEC document |
| October 06, 2016 Filed Oct 7, 2016 16:53 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 150,000 | $0.00 Strike: $8.71 | $0.00 |
DisclosureSEC source: 0001209191-16-145417 · doc4.xml · derivative · entry 1 White Barbara · CIK 0001625844 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-10-06 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on October 6, 2017, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on November 6, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.